Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentatio...
Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results Retail Sales Velocity Increasing +23.2% Year-over-Year1Improved Adj. EBITDA Loss by 35.2% Year-over-Year3Reiterating Net Sales Guidance Range of $24M to $30M PLANO, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months ended March 31, 2024. Q1 2024 – Improved Mix and Growing MomentumThe Company has continue...
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at . Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Fou...
Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Results PLANO, Texas, May 12, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today announces that it will release its fiscal 2024 first quarter results on Tuesday, May 14, 2024, after the market closes. In conjunction with the release, the Company has scheduled a conference call that will be hosted at 4:3...
Royalty Pharma Reports First Quarter 2024 Results Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We continued to execute on our strategy in the f...
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (N...
AVENTURA, Fla.--(BUSINESS WIRE)-- Immersion Corporation (Nasdaq: IMMR), a leading developer and provider of technologies for haptics, today reported financial results for the first quarter ended March 31, 2024. First Quarter Financial Summary1: Total revenues of $43.8 million, compared to $7.1 million in the first quarter of 2023. GAAP net income was $18.7 million, or $0.59 per diluted share, compared to GAAP net income of $8.3 million, or $0.25 per diluted share, in the first quarter of 2023. GAAP operating expenses of $27.2 million in the first quarter of 2024, compared to $3.8 mi...
OraSure Reports Q1 ’24 Revenue of $54.1 Million Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 Delivered initial orders for Syphilis Health Check™ as part of our distribution agreement with Diagnostics Direct BETHLEHEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, tod...
Comscore Reports First Quarter 2024 Results RESTON, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today reported financial results for the quarter ended March 31, 2024. Q1 2024 Financial Highlights Revenue for the first quarter was $86.8 million compared to $91.6 million in Q1 2023Net loss of $1.1 million compared to $8.7 million in Q1 2023Adjusted EBITDA of $8.1 million compared to $5.2 million in Q1 2023Ma...
Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of ...
Proximic by Comscore Recognized in AdExchanger’s 2024 Top 50 Programmatic Power Players List NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Proximic by Comscore, a division of Comscore Inc. (NASDAQ:SCOR) and a leading provider of audience and content targeting solutions for programmatic activation, today announced that it has been included in AdExchanger's prestigious 2024 Programmatic Power Players list. Compiled by one of the advertising industry's leading media authorities, the list spotlights the top agencies and strategic tech partners in the digital advertising industry. Proximic by...
Moody's Ratings ("Moody's") affirmed the Baa3 senior unsecured ratings of Royalty Pharma plc ("Royalty Pharma"). At the same time, Moody's revised the outlook to positive from stable. The revision of the outlook to positive from stable reflects the potential for expanding cash flows and revenue di...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.